Targeted α Therapies for the Treatment of Bone Metastases

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

(2018) Christopher C. Parker et al.   EUROPEAN UROLOGY

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

(2017) Clemens Kratochwil et al.   JOURNAL OF NUCLEAR MEDICINE

The 23rd Annual Prostate Cancer Foundation Scientific Retreat report

(2017) Andrea K. Miyahira et al.   PROSTATE

Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma

(2017) Urs B. Hagemann et al.   Oncotarget

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS): Table 6:

(2016) N. I. Cherny et al.   ANNALS OF ONCOLOGY

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

(2016) Yana Dekempeneer et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

225Ac-PSMA-617 for PSMA-Targeted  -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

(2016) C. Kratochwil et al.   JOURNAL OF NUCLEAR MEDICINE

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

(2016) Fred Saad et al.   LANCET ONCOLOGY

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia

(2016) U. B. Hagemann et al.   MOLECULAR CANCER THERAPEUTICS

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA

(2016) Oliver Sartor et al.   PROSTATE

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state

(2015) K. Chi et al.   ANNALS OF ONCOLOGY

Integrating Bone Targeting Radiopharmaceuticals Into the Management of Patients With Castrate-Resistant Prostate Cancer With Symptomatic Bone Metastases

(2015) Seth R. Blacksburg et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP).

(2015) Nicholas J. Vogelzang et al.   JOURNAL OF CLINICAL ONCOLOGY

The evolutionary history of lethal metastatic prostate cancer

(2015) Gunes Gundem et al.   NATURE

Molecular Targeted α-Particle Therapy for Oncologic Applications

(2014) Thaddeus J. Wadas et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease

(2014) Robert Coleman et al.   BREAST CANCER RESEARCH AND TREATMENT

The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond

(2014) Jörgen Elgqvist et al.   Frontiers in Oncology

Visceral Disease in Castration-resistant Prostate Cancer

(2013) Carmel J. Pezaro et al.   EUROPEAN UROLOGY

Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis

(2013) Mari I. Suominen et al.   JNCI-Journal of the National Cancer Institute

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radionuclide Therapy of Bone Metastases

(2012) Manfred Fischer et al.   Breast Care

Paving the Way to Personalized Medicine: Production of Some Promising Theragnostic Radionuclides at Brookhaven National Laboratory

(2012) Suresh C. Srivastava   SEMINARS IN NUCLEAR MEDICINE

The contribution of Marie Skłodowska-Curie to the development of modern oncology

(2011) Andrzej Kułakowski   ANALYTICAL AND BIOANALYTICAL CHEMISTRY